Stockscreener 앱 받기
2.80
0.53%
-0.015
시간 외 거래:
2.80
전일 마감가:
$2.815
열려 있는:
$2.8
하루 거래량:
352.81K
Relative Volume:
0.77
시가총액:
$180.52M
수익:
-
순이익/손실:
$-37.30M
주가수익비율:
-4.7353
EPS:
-0.5913
순현금흐름:
$-30.62M
1주 성능:
-11.39%
1개월 성능:
-4.44%
6개월 성능:
-41.67%
1년 성능:
+78.34%
1일 변동 폭
$2.63
$2.825
1주일 범위
$2.63
$3.312
52주 변동 폭
$1.12
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
명칭
Galectin Therapeutics Inc
전화
678-620-3186
주소
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.80 | 181.49M | 0 | -37.30M | -30.62M | -0.5913 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 재개 | H.C. Wainwright | Buy |
| 2020-08-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-13 | 개시 | B. Riley FBR | Buy |
| 2017-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-19 | 개시 | ROTH Capital | Buy |
| 2017-03-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | 다운그레이드 | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-09-21 | 개시 | H.C. Wainwright | Buy |
| 2014-08-01 | 다운그레이드 | Aegis Capital | Buy → Hold |
| 2014-07-30 | 재확인 | MLV & Co | Buy |
| 2014-07-29 | 재확인 | MLV & Co | Buy |
| 2014-04-02 | 재확인 | MLV & Co | Buy |
| 2014-02-10 | 재확인 | Aegis Capital | Buy |
| 2014-01-09 | 재확인 | Aegis Capital | Buy |
| 2013-12-03 | 개시 | MLV & Co | Buy |
| 2013-08-19 | 재확인 | Aegis Capital | Buy |
모두보기
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics Stock (ISIN: US3631621074) Faces Investor Scrutiny Amid Legal Probe and Earnin - AD HOC NEWS
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board By Investing.com - Investing.com India
Galectin Therapeutics Inc. Appoints Henry Brem, M.D. as Independent Director to Board of Directors - marketscreener.com
Sentiment Recap: Is Galectin Therapeutics Inc forming a double bottom2026 Trade Ideas & Consistent Growth Equity Picks - baoquankhu1.vn
Galectin Therapeutics Appoints Dr. Henry Brem to Board, Advancing Belapectin for MASH Cirrhosis and Cancer Therapies - Minichart
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board - Investing.com
Galectin Therapeutics (GALT) director awarded 60,000 stock options at $3.1600 - Stock Titan
Director Henry Brem joins Galectin (GALT) board and reports zero share ownership - Stock Titan
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. - Bitget
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board - TipRanks
Henry Brem, M.D. joins Galectin Therapeutics (GALT) Board as independent director - Stock Titan
Portfolio Shifts: Whats the outlook for Galectin Therapeutics Incs sectorTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Recap Report: Is Galectin Therapeutics Inc forming a double bottomQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps - Yahoo Finance
Take Profit: Does Galectin Therapeutics Inc have a sustainable dividendJuly 2025 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Panic Selling: Will Galectin Therapeutics Inc outperform its industry peers2025 Price Momentum & Weekly Stock Breakout Alerts - baoquankhu1.vn
Highs Report: Is Galectin Therapeutics Inc forming a double bottomJuly 2025 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Buyout Rumor: Can Galectin Therapeutics Inc weather a recessionJuly 2025 Summary & Reliable Intraday Trade Alerts - baoquankhu1.vn
GALT Should I Buy - Intellectia AI
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET - marketscreener.com
Belapectin Phase 3 data: potential first treatment for MASH varices - Stock Titan
GALT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GALT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT - TipRanks
Is Galectin Therapeutics Inc. in a bullish channel2025 Short Interest & Weekly Breakout Watchlists - mfd.ru
Trend Review: Is Galectin Therapeutics Inc in a bullish channelJuly 2025 Decliners & AI Forecast Swing Trade Picks - baoquankhu1.vn
Does Galectin Therapeutics Inc. have a sustainable dividendWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
Is Galectin Therapeutics Inc stock a buy or sell2025 Earnings Surprises & Low Risk High Win Rate Picks - baoquankhu1.vn
What is the long term forecast for Galectin Therapeutics Inc. stock2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
GALT PE Ratio & Valuation, Is GALT Overvalued - Intellectia AI
Will Galectin Therapeutics Inc. stock deliver long term returns2025 Volatility Report & Safe Capital Allocation Plans - mfd.ru
What’s the outlook for Galectin Therapeutics Inc.’s sectorMarket Growth Review & Fast Exit/Entry Strategy Plans - mfd.ru
Buy Signal: Whats the outlook for Galectin Therapeutics Incs sectorPortfolio Return Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Is Galectin Therapeutics Inc. stock a dividend growth opportunityQuarterly Profit Summary & Weekly High Conviction Trade Ideas - mfd.ru
Short Covering: How is MLKN managing supply chain issues2025 Trading Recap & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Chart Watch: Is Galectin Therapeutics Inc gaining market shareJuly 2025 Recap & Accurate Intraday Trade Tips - baoquankhu1.vn
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap dropped US$39m last week; Individual investors bore the brunt - simplywall.st
Can Galectin Therapeutics Inc expand into new marketsJobs Report & Real-Time Volume Analysis - baoquankhu1.vn
Meme Stocks: Will Galectin Therapeutics Inc outperform its industry peersMarket Activity Report & Expert Approved Momentum Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - yourwyominglink.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders - Yahoo Finance
Moving Averages: What is the Moat Score of WVVIPBuy Signal & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Analysis Recap: Can Galectin Therapeutics Inc be the next market leaderTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Portfolio Update: Is DNAWS a potential multi baggerEarnings Beat & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update - MarketBeat
Galectin Therapeutics Under Investigation, Stock Plummets 28.9% - Intellectia AI
Is Galectin Therapeutics Inc. gaining market shareJuly 2025 Analyst Calls & Safe Entry Point Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Buy: Can BROG navigate macro headwindsWeekly Investment Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Growth Review: Is Galectin Therapeutics Inc stock affected by interest rate hikesQuarterly Earnings Report & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics Inc (GALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):